đź“Š Evidence-Based Reference
Optilume Urethral Drug Coated Balloon
Urotronic
Summary: The Optilume urethral drug-coated balloon is a device used for treating urethral stricture disease. It combines mechanical dilation with localized drug delivery to reduce recurrence rates. Key evidence suggests it may be more effective than conventional treatments.
FDA Clearance Information
Pathway ?
PMA
Number ?
P210020 ↗
Decision Date ?
May 17, 2022
Product Code ?
QRH
Device Class ?
Class 3
Evidence ?
0 studies
The Optilume urethral drug-coated balloon by Urotronic was cleared through the PMA pathway on May 17, 2022. It is classified as a Class 3 medical device.
What It Is
The Optilume urethral drug-coated balloon is designed to treat urethral strictures by mechanically dilating the urethra while delivering paclitaxel, an antiproliferative drug, to prevent scar tissue formation. It is intended for use in patients with recurrent urethral strictures.
FDA-Cleared Indications
- FDA approval includes validation of a new low-ethylene-oxide sterilization cycle using lower ethylene oxide concentration and shorter ethylene oxide dwell time.
- The underlying device indication is treatment of recurrent anterior urethral strictures in appropriately selected adult patients, according to the device labeling.
Clinical Applications
- Endoscopic treatment of recurrent anterior urethral stricture disease.
- Balloon dilation of a urethral stricture with simultaneous local delivery of paclitaxel.
- Treatment of selected recurrent strictures as an alternative to repeated conventional dilation or direct visual internal urethrotomy.
Reported off-label uses
- Use in urethral stricture locations, lengths, or patient groups outside the device labeling.
- Use for other scar-related urinary tract narrowings, such as bladder neck contracture or vesicourethral anastomotic stenosis.
Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.
Evidence Summary
The literature includes 15 studies, comprising systematic reviews, meta-analyses, and randomized controlled trials, involving approximately 457 patients. The studies span from recent years up to 2025.
Reported Outcomes
Published studies report that the Optilume drug-coated balloon is effective in reducing the recurrence of urethral strictures. It has been shown to improve quality of life and may lower the need for re-treatment compared to standard endoscopic management. The ROBUST III trial demonstrated its efficacy over a 2-year follow-up period.
Safety Profile
Reported complications include typical post-procedural discomfort and transient urinary symptoms. No significant adverse events were highlighted in the studies, indicating a favorable safety profile.
Evidence Limitations
Current evidence is limited by the relatively short follow-up periods and the need for more diverse patient populations. Further research is needed to confirm long-term efficacy and safety across different clinical settings.
Practical Considerations
- The device is available in multiple balloon diameters and lengths; selection depends on the urethral anatomy and stricture characteristics.
- It is delivered through the urethra over a guidewire under endoscopic and/or fluoroscopic guidance, with local, regional, or general anesthesia or sedation depending on the procedure.
- Patients with active urinary tract infection, unsuitable anatomy, or contraindications to balloon dilation or paclitaxel require careful evaluation before treatment.
- MRI safety depends on the specific device configuration and labeling; the product's current instructions for use should be checked before MRI.
- The device is not a permanent implant. Stricture recurrence remains possible, and follow-up with a urologist is required.
Frequently Asked Questions
What are the clinical indications for Optilume urethral drug-coated balloon?
The Optilume balloon is indicated for the treatment of recurrent anterior urethral strictures, particularly those that are small and located in the anterior urethra.
What outcomes have been reported in clinical studies?
Studies report reduced recurrence rates of urethral strictures and improved quality of life. The device may lower the need for re-treatment compared to conventional methods.
What complications have been reported?
Reported complications include transient urinary symptoms and post-procedural discomfort, with no significant adverse events noted in the studies.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.